Web: www.taiclone.com
Tel: +886-2-2735-9682
Email: order@taiclone.com

Tolvaptan

Catalog No: tcsc0572

Available Sizes

Size: 10mg

Size: 50mg

Specifications

CAS No:
150683-30-0

Formula:
$C_{26}H_{25}ClN_2O_3$

Pathway:
GPCR/G Protein;Autophagy

Target:
Vasopressin Receptor;Autophagy

Purity / Grade:
>98%

Solubility:
DMSO : ≥ 100 mg/mL (222.75 mM)

Alternative Names:
OPC-41061

Observed Molecular Weight:
448.94

Product Description

Tolvaptan is a selective, competitive arginine vasopressin receptor 2 antagonist with an IC50 of 1.28μM for the inhibition of AVP-induced platelet aggregation.

Web: www.taiclone.com
Tel: +886-2-2735-9682
Email: order@taiclone.com

IC50 value: 1.28 uM (inhibition of AVP-induced platelet aggregation)

Target: vasopressin receptor 2

Tolvaptan (OPC-41061) is a selective, competitive arginine vasopressin receptor 2 antagonist with an IC50 of 1.28μM for the inhibition of AVP-induced platelet aggregation. Tolvaptan (OPC-41061) is used to treat hyponatremia (low blood sodium levels) associated with congestive heart failure, cirrhosis, and the syndrome of inappropriate antidiuretic hormone (SIADH). Tolvaptan (OPC-41061) is also in fast-track clinical trials for polycystic kidney disease. Treatment with t tolvaptan (OPC-41061) causes rapid and sustained body weight reductions concurrent with increases in urine output, improves and/or normalizes serum sodium in hyponatremic patients, reduces signs and symptoms of congestion and increases thirst. However, tolvaptan (OPC-41061) has not been shown to decrease heart failure re-hospitalization or mortality. As an adjunct to standard therapy, tolvaptan (OPC-41061) is unique in that it is virtually the only novel agent tested in patients hospitalized for acute heart failure syndrome (AHFS) to reach its primary end point for short-term efficacy without causing deleterious side effects.